Results 31 to 40 of about 838,554 (221)

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Frontiers in Medicine
Meningitis caused by Acinetobacter species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality.
Jacob W. Snowdin, Nicholas J. Mercuro, Michael P. Madaio, Stephen A. Rawlings   +3 more
doaj   +1 more source

Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

Microbiology Spectrum, 2022
Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and ...
Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Alba Bellés, Juan Carlos Vázquez-Ucha, Jorge Arca-Suárez, Carlos Fernández-Lozano, German Bou, Alejandro Beceiro   +7 more
doaj   +1 more source

Heterocyclic Diaryliodonium-Based Inhibitors of Carbapenem-Resistant Acinetobacter baumannii

Microbiology Spectrum, 2023
Discovery of novel antibiotics targeting multidrug-resistant (MDR) pathogens such as A. baumannii is an urgent, unmet medical need. Our work has highlighted the potential of this unique scaffold to annihilate MDR A. baumannii alone and in combination with amikacin both in vitro
Pooja Kumari, Grace Kaul, T. Anand Kumar, Abdul Akhir, Manjulika Shukla, Suraj Sharma, Siddhesh S. Kamat, Sidharth Chopra, Harinath Chakrapani   +8 more
openaire   +2 more sources

Molecular epidemiology and antimicrobial susceptibility of Pseudomonas spp. and Acinetobacter spp. from clinical samples at Jimma medical center, Ethiopia

Frontiers in Microbiology, 2022
IntroductionPseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) can cause difficult-to-treat infections. We characterized molecular epidemiology of ceftazidime-resistant P. aeruginosa and carbapenem-resistant A. baumannii at
Tsegaye Sewunet, Daniel Asrat, Yimtubezinash Woldeamanuel, Abraham Aseffa, Christian G. Giske, Christian G. Giske   +5 more
doaj   +1 more source

Hydrogels Augmented With Artificial Sweeteners can Inhibit Multidrug‐Resistant Acinetobacter baumannii Growth and Biofilm Formation While Demonstrating Safety in Pre‐Clinical Pilot Human Trials

Advanced Healthcare Materials, EarlyView.
Using PVA–borax hydrogels as carriers for off‐the‐shelf artificial sweeteners to fight multidrug‐resistant A. baumannii. These soft, biocompatible hydrogels rapidly reduce bacterial viability within multidrug‐resistant A. baumannii biofilms by more than 99% within one hour and sustain antimicrobial activity over time, while demonstrating safety in both
Jie Han, Mohamed Soliman, Bin Zhang, Dominika Krawiel, Ronan R. McCarthy   +4 more
wiley   +1 more source

Rapid Multiplex Antimicrobial Resistance Profiling and Bacterial Identification by LAP‐MALDI Mass Spectrometry Biotyping

Advanced Science, EarlyView.
Liquid atmospheric pressure matrix‐assisted laser desorption/ionization (LAP‐MALDI) mass spectrometry (MS) provides multiplexed biotyping of microbial cultures using a fast and simple workflow. This is demonstrated for clinically relevant bacteria, resulting in accurate antimicrobial resistance (AMR) detection, speciation by MS/MS sequencing and ...
Lily R. Adair, Shabnam Iyer, Ian M. Jones, Rainer Cramer   +3 more
wiley   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Acinetobacter baumannii and Its Relationship to Carbapenem Resistance: A Meta-Analysis

Bacteria, 2022
Infections by antibiotic-resistant bacteria are a significant and complex global health issue. In this context, Acinetobacter baumannii is particularly important because of its ability to withstand treatments by β-lactams, such as carbapenem. The objective of this work was to investigate, through systematic analysis and meta-analysis, the chance of ...
Diego Lucas Neres Rodrigues, Francielly Morais Rodrigues da Costa, Wanderson Marques da Silva, Flavia Aburjaile, Vasco Azevedo   +4 more
openaire   +3 more sources

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

iLABMED, EarlyView.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

The global epidemiology of carbapenem-resistant Acinetobacter baumannii

JAC-Antimicrobial Resistance
Abstract Carbapenem-resistant Acinetobacter baumannii (CRAb) is a challenging, environmentally hardy organism with a propensity to spread within hospitals and a predilection to infect critically ill, vulnerable patients. With its potential for rapid transmission, limited treatment options, and substantial mortality, CRAb is recognized as
Angelique Boutzoukas, Yohei Doi
openaire   +2 more sources